Grifols, S.A. (NASDAQ:GRFS) Stock Position Lifted by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its position in Grifols, S.A. (NASDAQ:GRFS) by 144.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,002,511 shares of the biotechnology company’s stock after acquiring an additional 1,181,959 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.29% of Grifols worth $17,782,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in GRFS. GAMMA Investing LLC increased its stake in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 1,135 shares during the last quarter. Signaturefd LLC grew its position in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 2,153 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Grifols during the 2nd quarter valued at about $89,000. HighTower Advisors LLC lifted its holdings in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 1,546 shares during the last quarter. Finally, Tidal Investments LLC bought a new position in Grifols in the third quarter worth about $147,000.

Grifols Price Performance

GRFS stock opened at $7.60 on Friday. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $9.96. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The stock’s fifty day moving average is $8.08 and its two-hundred day moving average is $8.16.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.